Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours

Drug resistance remains a major challenge in the clinical treatment of gastrointestinal stromal tumours (GISTs). While acquired on‐target mutations of mast/stem cell growth factor receptor (KIT) kinase is the major resistance mechanism, activation of alternative signalling pathways may also play a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Juan, Gao, Jingjing, Wang, Aoli, Jiang, Zongru, Qi, Shuang, Qi, Ziping, Liu, Feiyang, Yu, Kailin, Cao, Jiangyan, Chen, Cheng, Hu, Chen, Wu, Hong, Wang, Li, Wang, Wenchao, Liu, Qingsong, Liu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019892/
https://www.ncbi.nlm.nih.gov/pubmed/35194937
http://dx.doi.org/10.1002/1878-0261.13199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019892/
https://www.ncbi.nlm.nih.gov/pubmed/35194937
http://dx.doi.org/10.1002/1878-0261.13199

Ejemplares similares